Experts Recommend Requiring Randomized Trials For Flow Diverter PMAs
This article was originally published in The Gray Sheet
Executive Summary
FDA's Neurological Devices Panel says sponsors should be required to conduct randomized controlled trials for aneurysm treatment devices such as flow diverters and should only be allowed to use performance goal studies as a last resort to support approval.
You may also be interested in...
Brain Trust Advises US FDA On Aneurysm Device Trials
To help figure out how intracranial aneurysm devices should be evaluated in clinical trials, US FDA brought together its Neurological Devices Advisory Panel. The experts answered questions ranging from safety and efficacy endpoints that should be taken into consideration to post-market study requirements.
Aneurysm Devices In The Regulatory Spotlight: US FDA Panel Meeting Set For March
The agency scheduled a Neurological Devices Panel meeting for March 1 to consider appropriate clinical design and data expectations for intracranial aneurysm devices.
FDA Plans Acute Stroke Device Workshop; Guidance Could Follow
The October workshop will focus discussion on clinical study trial designs, patient populations, and patient selection methods, as well as study endpoints for devices targeting ischemic stroke, FDA says.